A key driver of microarray consumption in cancer research is the need for early detection and therapeutic intervention to develop targeted treatment options.
Microarrays have expanded far beyond their early use as simple gene-expression profiling tools and now have applications that span the genomic gamut.
While falling prices and maturing technology are causing NGS to make headway in becoming the technology of choice for a wide range of applications, the transition away from microarrays is a long and varied one. Regardless of which technology they choose, genomic researchers have never had more options.
Experts are divided on the fate of this segment. Whereas some are confidently predicting the ultimate demise of microarrays, to be replaced by some newer, advanced technology, others are maintaining that sky is still the limit for the technology that had some very simple beginnings and blossomed into a fundamental laboratory tool.
The microarray-based tests share the largest portion of the molecular diagnostics market with PCR-based tests. The market is expected to grow by 15 percent in the coming years.